Michelle Phillips Hudspeth, MD

MUSC Health, located in Charleston, SC, is a comprehensive healthcare system dedicated to providing high-quality medical services and patient-centered care to individuals across South Carolina. The organization emphasizes advanced medical practices, research initiatives, and community involvement to enhance healthcare accessibility and collaboration. Offering a wide range of services, MUSC Health specializes in areas such as cancer treatment, cardiac care, rehabilitation, and women's health, among others. With a commitment to innovation, education, and compassionate care, MUSC Health aims to improve the health and well-being of its patients and the communities it serves. Generated from the website

This provider is no longer seeing patients at MUSC Health.

Patrick Flume is a Distinguished Professor of Medicine and Pediatrics at the Medical University of South Carolina. He serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis and oversees a large Cystic Fibrosis (CF) Center, including the largest adult CF program in South Carolina. He also leads large clinical programs dedicated to patients with bronchiectasis and non-tuberculous mycobacterial (NTM) infections. He is recognized by the national and international CF community having served on the CF Foundation Center Committee, the Adult Care Consensus Committee, and the Advisory Task Force on Adult Issues, the Professional Education Committee, the European CF Society’s Best Practices committee, and as founding co-chair of the CF Foundation’s Pulmonary Practice Guidelines Committee. He co-led the International Working Group on Antimicrobial Resistance in Cystic Fibrosis. He is the Editor-in-Chief for the Journal of Cystic Fibrosis. He serves as Associate Vice President for Clinical Research at MUSC, leads a very busy clinical research program for CF, bronchiectasis, and NTM, and is co-principal investigator for the South Carolina Clinical & Translational Research Institute. Many of these studies are related to new drug and therapy development for patients, but he also has an interest in determining optimal management of CF pulmonary exacerbations and is the co-PI in the STOP trials, aimed at identifying optimal treatments for exacerbations.